The Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity

被引：0
|
作者：
Jain, Sidharth S. [1 ]
Burton Sojo, Giselle [1 ]
Sun, Harry [1 ]
Friedland, Benjamin N. [1 ]
Mcnamara, Megan E. [1 ]
Schmidt, Marcel O. [1 ]
Wellstein, Anton [1 ]
机构：
[1] Georgetown Univ, Georgetown Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 13期
基金：
美国国家卫生研究院;
关键词：
immune checkpoint inhibitor; aging; cellular senescence; immune-related adverse events; T-CELL RESPONSES; ADVERSE EVENTS; DNA-DAMAGE; SUPPRESSOR-CELLS; TUMOR-SUPPRESSOR; CANCER; FIBROBLASTS; CLEARANCE; PD-1; AGE;
D O I：
10.3390/ijms25137013
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Cellular senescence accumulates with age and has been shown to impact numerous physiological and pathological processes, including immune function. The role of cellular senescence in cancer is multifaceted, but the impact on immune checkpoint inhibitor response and toxicity has not been fully evaluated. In this review, we evaluate the impact of cellular senescence in various biological compartments, including the tumor, the tumor microenvironment, and the immune system, on immune checkpoint inhibitor efficacy and toxicity. We provide an overview of the impact of cellular senescence in normal and pathological contexts and examine recent studies that have connected aging and cellular senescence to immune checkpoint inhibitor treatment in both the pre-clinical and clinical contexts. Overall, senescence plays a multi-faceted, context-specific role and has been shown to modulate immune-related adverse event incidence as well as immune checkpoint inhibitor response.
引用
收藏
页数：20
相关论文
共 50 条
  • [21] Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician
    Hansen, Eric D.
    Wang, Xiao
    Case, Amy A.
    Puzanov, Igor
    Smith, Tom
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2018, 56 (03) : 460 - 472
  • [22] Immune checkpoint inhibitor and encephalic radiotherapy: Toxicity and Adverse events
    Matteucci, P.
    Santo, B.
    Ippolito, E.
    Zuccoli, P.
    Petrianni, G. M.
    Trecca, P.
    Gentile, S.
    Miele, M.
    Palizzi, S.
    Trodella, L.
    D'Angelillo, R. M.
    Ramella, S.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S678 - S678
  • [23] Management of multiorgan failure caused by immune checkpoint inhibitor toxicity
    Verma, Tushita
    Jawadi, Altamash
    Ahmed, Shozab
    BMJ CASE REPORTS, 2025, 18 (02)
  • [24] Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
    Kang, Jee Hye
    Bluestone, Jeffrey A.
    Young, Arabella
    TRENDS IN IMMUNOLOGY, 2021, 42 (04) : 293 - 311
  • [25] Immune checkpoint inhibitor toxicity in the clinical practice setting.
    Schmidt, Laura
    McGuire, Brian
    Hui, Wendy
    Carro, George W.
    Hensing, Thomas A.
    Shevrin, Daniel H.
    Campbell, Nicholas Paul
    Hanson, Britt Erika
    Brockstein, Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
    Sieber, Brendan
    Strauss, Julius
    Li, Zihai
    Gatti-Mays, Margaret E.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Role of telomeres and the senescence response in cancer and aging
    Campisi, J
    FASEB JOURNAL, 2006, 20 (05): : A890 - A890
  • [28] Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
    Morad, Golnaz
    Helmink, Beth A.
    Sharma, Padmanee
    Wargo, Jennifer A.
    CELL, 2021, 184 (21) : 5309 - 5337
  • [29] Predicting immune checkpoint inhibitor response with mathematical modeling
    Butner, Joseph D.
    Wang, Zhihui
    IMMUNOTHERAPY, 2021, 13 (14) : 1151 - 1156
  • [30] An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy
    Rimm, David L.
    JAMA ONCOLOGY, 2023, 9 (01) : 60 - 61
12345